CO5261557A1 - Formulacion farmaceutica que comprende 9-[2[[bis[pivaloiloxi metil]fosfono]metoxi]etil]adenina y un excipiente alcalino - Google Patents

Formulacion farmaceutica que comprende 9-[2[[bis[pivaloiloxi metil]fosfono]metoxi]etil]adenina y un excipiente alcalino

Info

Publication number
CO5261557A1
CO5261557A1 CO99077816A CO99077816A CO5261557A1 CO 5261557 A1 CO5261557 A1 CO 5261557A1 CO 99077816 A CO99077816 A CO 99077816A CO 99077816 A CO99077816 A CO 99077816A CO 5261557 A1 CO5261557 A1 CO 5261557A1
Authority
CO
Colombia
Prior art keywords
adenine
bis
ethyl
pivaloiloxi
metoxi
Prior art date
Application number
CO99077816A
Other languages
English (en)
Inventor
Terrence C Dahl
J Yuan Lung-Chi
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/211,613 external-priority patent/US6635278B1/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CO5261557A1 publication Critical patent/CO5261557A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Abstract

Una composición que comprende 9-[2-[[bis[(pivaloiloxi)metiI]fosfono]metoxi]etiI]adenina y un excipiente alcalino.2Un método para estabilizar 9-[2-[[bis[(pivaloiloxi)metil]fosfono]metoxi]etil]adenina que comprende mezclar la 9-[2-[[bis[(pivaloiloxi)metil]fosfono]metoxi]etil]adenina con un excipiente alcalino. <EMI FILE="99077816_1" ID="1" IMF=JPEG >
CO99077816A 1998-12-15 1999-12-13 Formulacion farmaceutica que comprende 9-[2[[bis[pivaloiloxi metil]fosfono]metoxi]etil]adenina y un excipiente alcalino CO5261557A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11240398P 1998-12-15 1998-12-15
US09/211,613 US6635278B1 (en) 1998-12-15 1998-12-15 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
CO5261557A1 true CO5261557A1 (es) 2003-03-31

Family

ID=26809911

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99077816A CO5261557A1 (es) 1998-12-15 1999-12-13 Formulacion farmaceutica que comprende 9-[2[[bis[pivaloiloxi metil]fosfono]metoxi]etil]adenina y un excipiente alcalino

Country Status (19)

Country Link
EP (1) EP1140114B1 (es)
JP (1) JP4750946B2 (es)
KR (1) KR100624214B1 (es)
CN (2) CN100361664C (es)
AR (1) AR021670A1 (es)
AT (1) ATE298576T1 (es)
AU (1) AU759869B2 (es)
BR (1) BRPI9916820B8 (es)
CA (1) CA2355239C (es)
CO (1) CO5261557A1 (es)
DE (1) DE69926012T2 (es)
ES (1) ES2245130T3 (es)
HK (1) HK1040488A1 (es)
ID (1) ID30032A (es)
MY (1) MY126526A (es)
NZ (1) NZ511855A (es)
TR (1) TR200101746T2 (es)
TW (1) TWI230618B (es)
WO (1) WO2000035460A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2536972T5 (es) * 2000-07-21 2022-04-06 Gilead Sciences Inc Profármacos de análogos de nucleótidos de fosfonato y métodos para seleccionar y preparar los mismos
KR20040028947A (ko) * 2001-07-31 2004-04-03 하. 룬트벡 아크티에 셀스카브 에시탈로프람 함유 결정 조성물
AU2003284800A1 (en) 2002-11-12 2004-06-03 Tianjin Kinsly Pharmaceutical Co., Ltd. A new crystal form of adefovir dipivoxil and its composition
EP1635847B1 (en) 2003-06-13 2019-07-31 IDH Holding ApS Treatment of symptoms associated with bacterial vaginosis
ITMI20071594A1 (it) 2007-08-02 2009-02-03 Solmag Spa Forma cristallina monoidrata di adefovir dipivoxil
KR20100031045A (ko) * 2008-09-11 2010-03-19 씨제이제일제당 (주) 아데포비어 디피복실의 정제방법
CN104173356A (zh) * 2008-09-17 2014-12-03 Cj第一制糖株式会社 肝适能固态分散物、包括其的药的组成物以及其制备方法
KR101089620B1 (ko) * 2009-07-20 2011-12-06 경희대학교 산학협력단 무수결정형 아데포비어 디피복실 및 이온성 액체를 사용한 이의 제조 방법
EP2343056A1 (en) 2009-12-30 2011-07-13 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Producing stable adefovir dipivoxil solid dispersions
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
CN108883091A (zh) * 2015-12-22 2018-11-23 X4 制药有限公司 用于治疗免疫缺陷病的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201726A (ja) * 1982-05-18 1983-11-24 Meiji Seika Kaisha Ltd 安定な製剤の製造法
CS263952B1 (en) * 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
US4704365A (en) * 1986-02-24 1987-11-03 Abbott Laboratories Composition and method for stabilization of dinucleotides
CA2035841C (en) * 1990-02-22 1996-02-13 Harry B. Demopoulos Storage-stable glucosamine sulphate oral dosage forms and methods for their manufacture
ATE167679T1 (de) * 1990-09-14 1998-07-15 Acad Of Science Czech Republic Wirkstoffvorläufer von phosphonaten
JPH0825905B2 (ja) * 1990-11-20 1996-03-13 武田薬品工業株式会社 医薬固形組成物用安定化剤および安定化方法
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
ATE178794T1 (de) * 1993-01-19 1999-04-15 Warner Lambert Co Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
JP2974550B2 (ja) * 1993-06-01 1999-11-10 ビオフェルミン製薬株式会社 経口投与用固体組成物
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
JP2762998B2 (ja) * 1997-04-25 1998-06-11 武田薬品工業株式会社 医薬固形組成物用安定化剤および安定化方法
JPH114666A (ja) * 1997-06-17 1999-01-12 Otsuka Pharmaceut Co Ltd マグネシウム補給発泡剤組成物
CA2596320C (en) * 1997-07-25 2008-12-23 Gilead Sciences, Inc. Nucleotide analog compositions

Also Published As

Publication number Publication date
ID30032A (id) 2001-11-01
HK1040488A1 (en) 2002-06-14
CN1202829C (zh) 2005-05-25
BRPI9916820B8 (pt) 2023-04-25
TWI230618B (en) 2005-04-11
CA2355239A1 (en) 2000-06-22
AR021670A1 (es) 2002-07-31
JP4750946B2 (ja) 2011-08-17
BRPI9916820A2 (pt) 2001-10-30
CN1682743A (zh) 2005-10-19
CN1330547A (zh) 2002-01-09
BRPI9916820B1 (pt) 2018-04-03
WO2000035460A2 (en) 2000-06-22
TR200101746T2 (tr) 2001-12-21
KR100624214B1 (ko) 2006-09-18
CN100361664C (zh) 2008-01-16
ATE298576T1 (de) 2005-07-15
DE69926012D1 (de) 2005-08-04
EP1140114A2 (en) 2001-10-10
NZ511855A (en) 2003-07-25
EP1140114B1 (en) 2005-06-29
CA2355239C (en) 2008-03-18
DE69926012T2 (de) 2006-05-04
WO2000035460A3 (en) 2000-11-09
ES2245130T3 (es) 2005-12-16
JP2002532429A (ja) 2002-10-02
AU2361300A (en) 2000-07-03
AU759869B2 (en) 2003-05-01
KR20010080765A (ko) 2001-08-22
MY126526A (en) 2006-10-31

Similar Documents

Publication Publication Date Title
CO5261557A1 (es) Formulacion farmaceutica que comprende 9-[2[[bis[pivaloiloxi metil]fosfono]metoxi]etil]adenina y un excipiente alcalino
CY1119742T1 (el) Βιολογικα συστηματα μεταφορας πολλαπλου-συστατικου
SE9702981D0 (sv) Dental implant systems
CO5070656A1 (es) Analogos de la rapamicina que contienen tetrazol con perio- dos de vida media mas cortos
ATE297200T1 (de) Facettenreiches verfahren zur unterdrückung der vermehrung latenter viren in menschen und tieren
ES2078551T3 (es) Medicamentos en aerosol.
CO5271716A1 (es) Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
NO985874D0 (no) Bestemte fosfinylderivater nyttige som naaladase inhibitorer
GT199900102A (es) Fenoxipropanolaminas, procedimiento para su preparacìon y composiciones farmacèuticasque las contienen.
CO5160257A1 (es) La n-piperidino-5-(4-bromofenil)-1-(2,4-diclorofenil)-4-etilpirazol-3-carboxamida, sus sales, su preparacion y las composiciones farmaceuticas que la contienen
DK0429624T3 (da) Radioimmunterapi under anvendelse af alfa-partikelemission
KR970702733A (ko) 활성물질의 방출 조절용 콜라겐 제제(collagen preparation the controlled release of active substances)
ES2146227T3 (es) Composiciones farmaceuticas que contienen nifedipina y procedimiento para su preparacion.
IL122737A0 (en) Salts of amidine derivative and cyclooxygenase inhibitors their preparation and pharmaceutical compositions containing them
CO5130008A1 (es) Composicion oral compactada famaceuticamente efectiva a base de entacapona, nitecapona y croscarmelasa de sodio y metodo para preparar dicha composicion
ID23857A (id) Senyawa-senyawa guanidinil heterosiklik yang berguna sebagai agonis adrenoceptor alfa-2
DK0772650T3 (da) Selvfrigørende bindemiddelsystem
AR023320A1 (es) Articulo absorbente desechable que comprende un miembro de manejo de materia fecal
BR9809571A (pt) Composição medicinal e processo para produzì-la
BR9807471A (pt) Uso do composto anti-cd40l
IS4673A (is) Ljósvirk fenýl pýrimidín afleiða sem kvalastillandi miðill
ES2105605T3 (es) Antagonistas de taquiquinina, su preparacion y utilizacion en formulaciones farmaceuticas.
DE59909016D1 (de) Künstliche Gelenkpfanne
EA199800553A1 (ru) Порошок вспенивателя и способ его получения
CO5221101A1 (es) Composiciones y metodos para reprimir insectos que deterioran cultivos de arroz y otros

Legal Events

Date Code Title Description
FG Application granted